Effect of 3-thienylalanine-ornithine-proline, new sulfur-containing angiotensin-converting enzyme inhibitor on blood pressure and oxidative stress in spontaneously hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 2, 2009, Pages 145-150

  Hanif, Kashif ^a   Snehlata, ^a   Pavar, Mahesh C ^a   Arif, Ehtesham ^a   Fahim, Mohammad ^b   Pasha, M A Qadar ^a   Pasha, Santosh ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b UNIVERSITY OF DELHI   (India)

Author keywords

ACE inhibitors; Antioxidant; Oxidative stress; Sulfhydryl group; Thiophene ring

Indexed keywords

3 THIENYLALANINE ORNITHINE PROLINE; ANTIOXIDANT; CAPTOPRIL; CATALASE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FREE RADICAL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; MALONALDEHYDE; NITRITE; SUPEROXIDE DISMUTASE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; ZINC; 3 THIENYLALANYL ORNITHYL PROLINE; 3-THIENYLALANYL-ORNITHYL-PROLINE; BIOLOGICAL MARKER; OLIGOPEPTIDE; SCAVENGER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENDOTHELIAL DYSFUNCTION; LIPID PEROXIDATION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; ANIMAL; BLOOD; DRUG EFFECT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; FREE RADICAL SCAVENGERS; OLIGOPEPTIDES; OXIDATIVE STRESS; RATS; RATS, INBRED SHR; THIOPHENES;

EID: 65549116759     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318197c616     Document Type: Article

References (33)

1. Petrillo EW, Ondetii MA. Angiotensin converting enzyme inhibitors: medicinal chemistry and biological action. Med Res Rev. 1982;2:1-41. (Pubitemid 12051910)
2. Erdos EG. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol. 1990;15(Suppl 6):S20-S24.
3. Jeserich M, Pape L, Just H, et al. Effect of long-term angiotensinconverting enzyme inhibition on vascular function in patients with chronic congestive heart failure. Am J Cardiol. 1995;76:1079-1082.
4. Thuillez C, Mulder P, Elfertak L, et al. Prevention of endothelial dysfunction in small and large arteries in a model of chronic heart failure. Effects of angiotensin converting enzyme inhibition. Am J Hypertens. 1995;8:7S-12S.
5. Katz SD. Mechanisms and implications of endothelial dysfunction in congestive heart failure. Curr Opin Cardiol. 1997;12:259-264. (Pubitemid 27252533)
6. Givertz MM, Colcucci WS. New targets for heart failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet. 1998; 352(Suppl 1):S135-S138.
7. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol. 1998;31: 1352-1356. (Pubitemid 28219127)
8. Hill MF, Singal PK. Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction. Circulation. 1997;96:2414-2420. (Pubitemid 27425850)
9. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production 12 via membrane NAD/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923. (Pubitemid 26129879)
10. Fukui T, Ishizaka N, Rajagopalan S, et al. p22 phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res. 1997;80:45-50. (Pubitemid 27030367)
11. Van Gilst WH, De Graeff PA, De Leeuw MJ, et al. Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exo- and endogenous nitrovasodilators. J Cardiovasc Pharmacol. 1991; 18:429-436.
12. Goldschmidt JE, Tallarida RJ. Pharmacological evidence that captopril possesses an endothelium-mediated component of vasodilation: effect of sulfhydryl groups on endothelium-derived relaxing factor. J Pharmacol Exp Ther. 1991;257:1136-1145.
13. Pasini AF, Garbin U, Nava MC, et al. Effect of sulfhydryl and nonsulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens. 2007;20:443-450. (Pubitemid 46441752)
14. Natesh R, Schwager SL, Sturrock ED, et al. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature. 2003;421: 551-554. (Pubitemid 36168450)
15. Patchett AA. The chemistry of enalapril. Br J Clin Pharmacol. 1984;18: 201S-207S.
16. Jones MJ, Oblatt R. Chemistry and applications of chelating agents in flotation and flocculation. In: Nagaraj DR, ed. Reagents in the Mineral Industry. London, UK: Institute of Mining and Metallurgy; 1997:209-220.
17. Bala M, Qadar Pasha MA, Bhardwaj DK, et al. Novel peptidomimics as angiotensin converting enzyme inhibitors: a combinatorial approach. Bioorg Med Chem. 2002;10:3685-3691.
18. Pavar MC, Hanif K, Azam A, et al. Structure-activity relationship study between ornithyl-proline and lysyl-proline based tripeptidomimics as angiotensin converting enzyme inhibitors. Bioorg Med Chem Lett. 2006; 16:2117-2121. (Pubitemid 43351062)
19. Green LC,Wagner DA, Glogowski J. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Anal Biochem. 1982;126:131-138. (Pubitemid 13203451)
20. Claiborne A. Catalase activity. In: Greenwald RA, ed. CRC Handbook of Methods in Oxygen Radical Research. Boca Raton, FL: CRC Press; 1985: 283-284.
21. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem. 1974;47:469-474.
22. Jollow DJ, Mitchell JR, Zampagilone N, et al. Bromobenzene induced liver necrosis: protective role and evidence for 3,4-bromobenzene oxide as hepatotoxic intermediate. Pharmacology. 1974;11:151-169.
23. Wright JR, Colby HD, Miles PR. Cytosolic factors that affect microsomal lipid peroxidation in lung and liver. Arch Biochem Biophys. 1981;206: 296-304.
24. Carlberg I, Mannervik B. Purification and characterization of the flavoenzyme glutathione reductase from rat liver. J Biol Chem. 1975; 250:5475-5480.
25. Mohandas J, Marshall JJ, Duggins GG, et al. Differential distribution of glutathione and glutathione related enzymes in rabbit kidney: possible implications in analgesic neuropathy. Cancer Res. 1984;44:5086-5091. (Pubitemid 14109449)
26. Jing TY, Zhao XY. The improved pyrogallol method by using terminating agent for superoxide dismutase measurement. Progr Biochem Biophys. 1995;22:84-86.
27. Halliwell B, Gutteridge JMC, Aruoma OI. The deoxyribose method: a simple test tube assay for determination of rate constants for reactions of hydroxyl radicals. Anal Biochem. 1987;165:215-219. (Pubitemid 17131019)
28. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411-1420.
29. Duchin KL, McKinstry DN, Cohen AI, et al. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clin Pharmacokinet. 1988;4:241-259. (Pubitemid 18111223)
30. Treiber A, Dansette PM, El Amri H, et al. Chemical and biological oxidation of thiophene: preparation and complete characterization of thiophene S-oxide dimers and evidence for thiophene S-oxide as an intermediate in thiophene metabolism in vivo and in vitro. J Am Chem Soc. 1997;119:1565-1571. (Pubitemid 27145499)
31. Hayek T, Pavlotzky E, Hamoud S, et al. Tissue angiotensin- convertingenzyme (ACE) deficiency leads to a reduction in oxidative stress and in atherosclerosis: studies in ACE-knockout mice type 2. Arterioscler Thromb Vasc Biol. 2003;23:2090. (Pubitemid 37433205)
32. Hornig B, Arakawa N, Haussmann D, et al. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation. 1998;98:2842-2848. (Pubitemid 29003965)
33. Fuster MD, Alyson E, Ochi MH, et al. Antioxidative activities of heterocyclic compounds formed in brewed coffee. J Agric Food Chem. 2000;48:5600-5603.